-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the IMbrave150 trial, compared with sorafenib, atezolizumab combined with bevacizumab can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients with unresectable hepatocellular carcinoma (HCC).
)
.
This article reports the results of the efficacy and safety analysis of the subgroup of Chinese patients in this trial
This article reports the results of the efficacy and safety analysis of the subgroup of Chinese patients in this trial
IMbrave150 is a global, randomized, open-label Phase 3 trial that recruits unresectable HCC patients who have not undergone systemic treatment
.
The test patients were randomly (2:1) divided into two groups, and received intravenous atezolizumab (1200 mg) combined with bevacizumab (15 mg/kg) (1 time/3 weeks) or sorafenib, respectively (400 mg, 2 times/day) treatment until intolerable toxicity or loss of clinical significance
From April 16, 2018 to April 8, 2019, a total of 194 Chinese patients were recruited (137 were in the overall study and 57 were in the extended study phase in China), of which 133 received atezolid Anti-combined bevacizumab treatment, 61 received sorafenib treatment
.
OS and PFS of the two groups
OS and PFS of the two groupsAs of August 29, 2019, the median OS of the combination group and sorafenib group were not up to 11.
4 months (adjusted hazard ratio [HR] 0.
44; 95%CI 0.
25-0.
76); the median PFS was 5.
7 vs 3.
2 months (HR 0.
60; 95% CI 0.
40-0.
90)
.
4 months (adjusted hazard ratio [HR] 0.
44; 95% CI 0.
25-0.
76); median PFS was 5.
7 vs 3.
2 months (HR 0.
60) ; 95%CI 0.
40-0.
90)
.
The median OS of the combination group and sorafenib group was not reached vs 11.
Adverse events
Adverse eventsThe incidence of grade 3-4 adverse events (AE) in the combination group and sorafenib group were 59.
1% (78/132) and 46.
6% (27/58), respectively
.
The most common grade 3-4 AE in the combination group was hypertension (15.
In summary, compared with sorafenib single-agent therapy, atezolizumab combined with bevacizumab can also significantly prolong the PFS and OS of Chinese patients with advanced HCC , suggesting that this combined regimen may become an option for Chinese patients with unresectable HCC.
Compared with sorafenib monotherapy, atezolizumab combined with bevacizumab can also significantly prolong the PFS and OS of patients with advanced HCC in China.
Original source:
Qin Shukui,Ren Zhenggang,Feng Yin-Hsun et al.
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study in this message